The original domain mapping supports a membrane-associated TLC-family protein; human experiments refine the compartment.

Current PAINT target records and donor premises were authenticated, but historical tree and ancestral placement were not reconstructed. Target function and source resolution are assessed separately.

The preserved UniProt subcellular vocabulary mappings concern ER and ERGIC membranes.

The combined automated ER sources include authenticated mouse Cln8 and a subcellular vocabulary term, with independent human location corroboration.

Human disease variants and the mouse mnd mutation identify CLN8; sequence analysis predicts a membrane protein. The selected original Results do not demonstrate a performed nervous-system developmental step.

The complete abstract proposes common NCL protein-catabolism roles and labels cathepsin D as CLN8 under historical nomenclature. It does not substantiate a protein-breakdown operation of the modern CLN8 membrane protein. Only the original abstract was accessible.

The authentic abstract directly reports human CLN8 ER/ERGIC localization and retrieval-motif effects. Original full journal access failed; the author thesis separately describes marker and motif experiments, and later full studies corroborate the compartment.

The authentic abstract identifies a TLC-family relationship and proposes lipid-related functions. The original full analysis remains inaccessible; this does not establish a specific CLN8 lipid-transport, ceramide-synthesis or proteolysis-regulatory assay.

The authentic abstract reports altered phospholipid and sphingolipid species in two human EPMR brain samples. Original full Methods and cholesterol-specific evidence were not recovered; the positive profiles are preserved without treating them as purified-enzyme reactions.

Selected original Methods and Results positively establish CLN8–CLN3 coimmunoprecipitation, with normal lymphoblast and transfected COS-7 contexts and stated antibody controls. Growth complementation does not prove a single molecular mechanism. The selected main cache remains an abstract; authentic external full text was read.

Selected original full Methods and Results include a CLN8-positive ceramide/GalCer lysate overlay despite a CLN3-centered title. The assay does not measure purified CLN8 affinity or lipid translocation. The genuine selected cache remains abstract-only.

The full paper shows CLN8 ER localization in HeLa cells and association with mouse CLN5 fusion protein in transfected-cell lysate. These are distinct species/construct contexts, and the pull-down does not establish a purified binary interaction.

Human cargo-recruitment, Sec24-tail interaction, motif-mutant and knockout/rescue experiments establish CLN8 as a COPII cargo receptor. Mouse lysosomal enzyme depletion is corroborating context, not the only basis for the human activity. Selected full Methods and Results were read.

Human tagged-construct assays and a HeLa-membrane/rat-cytosol budding system support cooperative CLN6–CLN8 recruitment and selective CLN8 COPII export. The subsequent corrigendum replaces Figure 2A, 5A and 7A panels; these corrections and the body/legend panel mismatch are explicitly retained. No precise disputed CLN6 deletion interval is adopted.

The authentic published correction replaces three panels in the EGRESS study. It is a corrigendum, not a retraction. The normal cached record is abstract-only, and the independent publisher correction and selected replacement panels were inspected in a bounded consultation.

The authentic abstract describes reduced ceramide in CLN8-deficient patient fibroblasts and cantharidin rescue of PP2A-linked phosphorylation changes, while the tested ER-to-Golgi ceramide conversion remains normal. Full original Methods remain inaccessible; no intrinsic phosphatase activity is assigned to CLN8.

Purified canonical-sequence human CLN8-HA acylates LPG using acyl-CoA to produce BMP; human knockout/rescue supports cellular BMP control. The tested LPG has a racemic headgroup and the product is not fully stereochemically resolved. CLN8 protein concentration was undetermined, so TLCD1 kinetics and mutant-catalysis controls are not attributed to CLN8. Selected actual Methods, Results, Figure 4 and supplement controls were independently assessed.